Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA®
Moderna, Inc. (NASDAQ: MRNA) announced today that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine designed to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. This approval, granted under a breakthrough therapy designation, marks the second approved […]
Understanding the 2024 Vaccination Updates: What You Need to Know
The CDC has announced several crucial updates to the vaccination schedules for both adults and children for the year 2024. These updates reflect advancements in vaccine development and changes in public health recommendations aimed at preventing a range of infectious diseases. Adult Vaccination Updates Respiratory Syncytial Virus (RSV) Vaccine: RSV is a respiratory virus that […]